Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAZMAN: AZD2811 and Durvalumab as Maintenance Therapy in Extensive Stage Small-Cell Lung Cancer
NCT04745689Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of defosbarasertib in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Feb 2021; status: active, not recruiting.
02
Drugs
defosbarasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04745689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745689.